City of Cape Coral Mun. Firefighters' Ret. Plan v. Emergent Biosolutions, Inc.
Opinion
ROGER W. TITUS, UNITED STATES DISTRICT JUDGE
This case involves alleged violations of federal securities laws by Defendant Emergent Biosolutions, Inc., HQ ("Emergent") and a number of Emergent executives, including Defendants Fuad El-Hibri, Daniel J. Abdun-Nabi ("Abdun-Nabi"), Robert G. Kramer, and Adam R. Havey ("Individual Defendants") (collectively, "Defendants"). Emergent is a specialty biopharmaceutical company and sole provider of the only U.S. Food and Drug Administration-licensed anthrax vaccine, BioThrax. Am. Compl. ¶¶ 34-35, ECF No.
*68023. The primary purchaser of BioThrax has been the United States Government via the Center for Disease Control and Prevention ("CDC"). Id. ¶ 35. In July 2010, the U.S. Biomedical Advanced Research and Development Authority awarded a six-year contract to Emergent to expand its BioThrax manufacturing capabilities at a new facility, Building 55. Id. ¶ 44.
In 2011, Emergent obtained a five-year BioThrax procurement contract from the CDC for Emergent to supply up to 44.75 million doses of BioThrax for the Strategic National Stockpile ("SNS"). Id. ¶ 41. This contract was set to expire on September 30, 2016. Id. In August 2015, Defendants began discussions with the CDC about the renewal of the BioThrax contract. Id. ¶ 46.
Plaintiffs allege that beginning on January 11, 2016, Defendants made material misrepresentations and omissions that made investors believe that the Government intended to purchase Emergent's newly increased production capacity. Id. ¶¶ 54-57. On May 5, 2016, in a press release filed with the U.S. Securities and Exchange Commission, Emergent confirmed that the Government would award it a renewed BioThrax contract and described the new contract as requiring "significantly increased deliveries in order to satisfy the U.S. government's stated requirements for a licensed anthrax vaccine in the Strategic National Stockpile" as well as making other related statements. Id. ¶¶ 55, 91. On a company conference call with investors on that same day, Abdun-Nabi, President and C.E.O. of Emergent, called the anticipated follow-on contract "one big, beautiful package." Id. ¶ 93.
From May 5, 2016 to June 1, 2016, the price of Emergent's Common Stock, which is traded on the New York Stock Exchange ("NYSE"), increased nearly fifteen percent, from $37.85 per share on May 5, 2016 to $43.49 per share on June 1, 2016. Id. ¶¶ 6, 15. On June 22, 2016, Emergent disclosed that the Government sought "the continued procurement of 29.4 million doses of BioThrax" over a five-year period, which was less than the expiring contract that called for 44.75 million. Id. ¶ 118. The same day, the price of Emergent Common Stock "declined by approximately $8 per share, falling from its close of $39.32 per share on June 21, 2016 to a close of $31.33 per share on June 22, 2016...on unusually high trading volume of more than 9.5 million shares traded, or 21 times the average daily trading volume over the preceding ten trading days." Id. ¶ 119.
On July 19, 2016, Plaintiff William Sponn ("Sponn"), individually and on behalf of all others similarly situated, initiated this lawsuit against Defendants, alleging violations of federal securities laws. Compl., ECF No. 1. On October 26, 2016, the Court granted Plaintiffs' Motion for Appointment as Lead Plaintiff and Approval of Selection of Lead Counsel (ECF No. 16), appointing Plaintiffs City of Cape Coral Municipal Firefighters' Retirement Plan ("Cape Coral Fire") and City of Sunrise Police Officers' Retirement Plan ("Sunrise Police") as Lead Plaintiffs and Robbins Geller Rudman & Dowd LLP ("Robbins Geller") as Lead Counsel pursuant to the Private Securities Litigation Reform Act (PSLRA) of 1995, 15 U.S.C. § 78u-4 (2012). ECF No. 22. On December 27, 2016, Lead Plaintiffs filed an Amended Complaint, asserting claims under Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 promulgated thereunder against all Defendants and claims under Section 20(a) of the Exchange Act against the Individual Defendants. ECF No. 23. On February 27, 2017, Defendants filed a Motion to Dismiss Plaintiffs' Amended Complaint ("Motion to Dismiss"). ECF No. 36. After a hearing, the Court denied the Motion to Dismiss by order on July 7, 2017. ECF No. 46.
*681Having prevailed on the Motion to Dismiss, Lead Plaintiffs returned with a Motion for Class Certification and Appointment of Class Representatives and Class Counsel, filed on November 29, 2017. ECF No. 60. On December 20, 2017, Lead Plaintiffs filed an Amended Motion for Class Certification and Appointment of Class Representatives and Class Counsel ("Amended Motion for Class Certification"), seeking to appoint Geoffrey L. Flagstad ("Flagstad") instead of Sponn, in addition to Lead Plaintiffs, as Class Representative.1 ECF No. 68. Defendants oppose class certification and ask the Court to strike the opinions in the Report on Market Efficiency of Lead Plaintiffs' expert. Defs.' Mot. to Exclude Expert Op., ECF No. 81. Having conducted a hearing on the pending motions, the Court will, for the reasons discussed below, certify the proposed Class based on a shortened Class Period.
1. The Proposed Class
In their Amended Motion, Lead Plaintiffs seek certification of a plaintiff class, pursuant to Federal Rule of Civil Procedure 23, consisting of:
All persons or entities who, between January 11, 2016 and June 21, 2016 (the "Class Period"), purchased or otherwise acquired Emergent BioSolutions Inc. publicly traded common stock listed on the New York Stock Exchange ("NYSE"), Inc. and who were damaged thereby.
ECF No. 69 at 2 (footnotes omitted). They seek to appoint themselves and Flagstad as Class Representatives. ECF No. 69 at 8. Cape Coral Fire and Sunrise Police are benefit pension plans that acquired 7,900 and 7,800 shares, respectively, of Emergent Common Stock during the proposed Class Period, but before May 5, 2016. Id. at 9. Flagstad is an individual who acquired 165 shares of Emergent Common Stock during the proposed Class Period, after May 5, 2016. Id. Finally, Lead Plaintiffs seek to appoint Robbins Geller, a law firm specializing in complex civil litigation cases and the current Lead Counsel, as Class Counsel. Id. at 1.
2. Legal Standard Under Rule 23
To maintain a class action, a party moving for class certification bears the burden of demonstrating that the proposed class meets the two-step inquiry outlined in Federal Rule of Civil Procedure 23. See Gunnells v. Healthplan Servs., Inc. ,
(1) Numerosity
Free access — add to your briefcase to read the full text and ask questions with AI
ROGER W. TITUS, UNITED STATES DISTRICT JUDGE
This case involves alleged violations of federal securities laws by Defendant Emergent Biosolutions, Inc., HQ ("Emergent") and a number of Emergent executives, including Defendants Fuad El-Hibri, Daniel J. Abdun-Nabi ("Abdun-Nabi"), Robert G. Kramer, and Adam R. Havey ("Individual Defendants") (collectively, "Defendants"). Emergent is a specialty biopharmaceutical company and sole provider of the only U.S. Food and Drug Administration-licensed anthrax vaccine, BioThrax. Am. Compl. ¶¶ 34-35, ECF No.
*68023. The primary purchaser of BioThrax has been the United States Government via the Center for Disease Control and Prevention ("CDC"). Id. ¶ 35. In July 2010, the U.S. Biomedical Advanced Research and Development Authority awarded a six-year contract to Emergent to expand its BioThrax manufacturing capabilities at a new facility, Building 55. Id. ¶ 44.
In 2011, Emergent obtained a five-year BioThrax procurement contract from the CDC for Emergent to supply up to 44.75 million doses of BioThrax for the Strategic National Stockpile ("SNS"). Id. ¶ 41. This contract was set to expire on September 30, 2016. Id. In August 2015, Defendants began discussions with the CDC about the renewal of the BioThrax contract. Id. ¶ 46.
Plaintiffs allege that beginning on January 11, 2016, Defendants made material misrepresentations and omissions that made investors believe that the Government intended to purchase Emergent's newly increased production capacity. Id. ¶¶ 54-57. On May 5, 2016, in a press release filed with the U.S. Securities and Exchange Commission, Emergent confirmed that the Government would award it a renewed BioThrax contract and described the new contract as requiring "significantly increased deliveries in order to satisfy the U.S. government's stated requirements for a licensed anthrax vaccine in the Strategic National Stockpile" as well as making other related statements. Id. ¶¶ 55, 91. On a company conference call with investors on that same day, Abdun-Nabi, President and C.E.O. of Emergent, called the anticipated follow-on contract "one big, beautiful package." Id. ¶ 93.
From May 5, 2016 to June 1, 2016, the price of Emergent's Common Stock, which is traded on the New York Stock Exchange ("NYSE"), increased nearly fifteen percent, from $37.85 per share on May 5, 2016 to $43.49 per share on June 1, 2016. Id. ¶¶ 6, 15. On June 22, 2016, Emergent disclosed that the Government sought "the continued procurement of 29.4 million doses of BioThrax" over a five-year period, which was less than the expiring contract that called for 44.75 million. Id. ¶ 118. The same day, the price of Emergent Common Stock "declined by approximately $8 per share, falling from its close of $39.32 per share on June 21, 2016 to a close of $31.33 per share on June 22, 2016...on unusually high trading volume of more than 9.5 million shares traded, or 21 times the average daily trading volume over the preceding ten trading days." Id. ¶ 119.
On July 19, 2016, Plaintiff William Sponn ("Sponn"), individually and on behalf of all others similarly situated, initiated this lawsuit against Defendants, alleging violations of federal securities laws. Compl., ECF No. 1. On October 26, 2016, the Court granted Plaintiffs' Motion for Appointment as Lead Plaintiff and Approval of Selection of Lead Counsel (ECF No. 16), appointing Plaintiffs City of Cape Coral Municipal Firefighters' Retirement Plan ("Cape Coral Fire") and City of Sunrise Police Officers' Retirement Plan ("Sunrise Police") as Lead Plaintiffs and Robbins Geller Rudman & Dowd LLP ("Robbins Geller") as Lead Counsel pursuant to the Private Securities Litigation Reform Act (PSLRA) of 1995, 15 U.S.C. § 78u-4 (2012). ECF No. 22. On December 27, 2016, Lead Plaintiffs filed an Amended Complaint, asserting claims under Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 promulgated thereunder against all Defendants and claims under Section 20(a) of the Exchange Act against the Individual Defendants. ECF No. 23. On February 27, 2017, Defendants filed a Motion to Dismiss Plaintiffs' Amended Complaint ("Motion to Dismiss"). ECF No. 36. After a hearing, the Court denied the Motion to Dismiss by order on July 7, 2017. ECF No. 46.
*681Having prevailed on the Motion to Dismiss, Lead Plaintiffs returned with a Motion for Class Certification and Appointment of Class Representatives and Class Counsel, filed on November 29, 2017. ECF No. 60. On December 20, 2017, Lead Plaintiffs filed an Amended Motion for Class Certification and Appointment of Class Representatives and Class Counsel ("Amended Motion for Class Certification"), seeking to appoint Geoffrey L. Flagstad ("Flagstad") instead of Sponn, in addition to Lead Plaintiffs, as Class Representative.1 ECF No. 68. Defendants oppose class certification and ask the Court to strike the opinions in the Report on Market Efficiency of Lead Plaintiffs' expert. Defs.' Mot. to Exclude Expert Op., ECF No. 81. Having conducted a hearing on the pending motions, the Court will, for the reasons discussed below, certify the proposed Class based on a shortened Class Period.
1. The Proposed Class
In their Amended Motion, Lead Plaintiffs seek certification of a plaintiff class, pursuant to Federal Rule of Civil Procedure 23, consisting of:
All persons or entities who, between January 11, 2016 and June 21, 2016 (the "Class Period"), purchased or otherwise acquired Emergent BioSolutions Inc. publicly traded common stock listed on the New York Stock Exchange ("NYSE"), Inc. and who were damaged thereby.
ECF No. 69 at 2 (footnotes omitted). They seek to appoint themselves and Flagstad as Class Representatives. ECF No. 69 at 8. Cape Coral Fire and Sunrise Police are benefit pension plans that acquired 7,900 and 7,800 shares, respectively, of Emergent Common Stock during the proposed Class Period, but before May 5, 2016. Id. at 9. Flagstad is an individual who acquired 165 shares of Emergent Common Stock during the proposed Class Period, after May 5, 2016. Id. Finally, Lead Plaintiffs seek to appoint Robbins Geller, a law firm specializing in complex civil litigation cases and the current Lead Counsel, as Class Counsel. Id. at 1.
2. Legal Standard Under Rule 23
To maintain a class action, a party moving for class certification bears the burden of demonstrating that the proposed class meets the two-step inquiry outlined in Federal Rule of Civil Procedure 23. See Gunnells v. Healthplan Servs., Inc. ,
(1) Numerosity: "the class is so numerous that joinder of all members is impracticable";
(2) Commonality: "there are questions of law or fact common to the class";
(3) Typicality: "the claims or defenses of the representative parties are typical of the claims or defenses of the class"; and
(4) Adequacy: "the representative parties will fairly and adequately protect the interests of the class.
Fed. R. Civ. P. 23(a)(1)-(4) ; Gunnells ,
3. The Proposed Class Meets the Rule 23 Standard
A. The Class Period
As a preliminary matter, the parties dispute the appropriate timeframe of the Class Period, assuming the Class is certified. Lead Plaintiffs propose that the Class Period should be from January 11, 2016, the date Lead Plaintiffs claim the alleged material misstatements about the follow-on contract began, through June 21, 2016, the day before the alleged "corrective" disclosure. ECF No. 69 at 2. Defendants argue that the Class Period should only begin on May 5, 2016, the date they assert the first actionable statement under the PSLRA was made, to June 21, 2016. Defs.' Opp'n to Lead Pls.' Am. Mot. for Class Certification 16, ECF No. 78. Although the Court has not made any final determinations regarding the materiality and actionability of any of the specifically alleged misstatements, it does recognize, as it did at the July 6, 2017 hearing on Defendants' Motion to Dismiss, that the May 5, 2016 statement by Abdun-Nabi calling the anticipated follow-on contract "one big, beautiful package," at this stage in the litigation "is where this case goes from puffery to fraud." Mots. Hr'g Tr. 97:20-21, ECF No. 79-3. Because the Court is required at the class certification stage to limit the proposed Class based on the alleged misrepresentations found to be actionable, the Court will at this time certify the proposed Class based on the shortened Class Period of May 5, 2016 to June 21, 2016 ("shortened Class Period"). See Malone v. Microdyne Corp. ,
Certification of the Class for the shortened Class Period necessarily results in the Court finding that Lead Plaintiffs cannot be appointed Class Representatives at this time because they do not meet the adequacy requirement under Rule 23(a)(4). Accordingly, only Flagstad is eligible to be appointed Class Representative. It does not result, however, in any impact on Lead Plaintiffs' ability to continue to serve and fulfill their duties as Lead Plaintiffs. Lead Plaintiffs may remain in the case and retain their obligations under the PSLRA and Rule 23 even when they are not appointed class representatives. See, e.g. , Lumen v. Anderson , No. 08-0514-CV-W-HFS,
*683B. The Proposed Class Satisfies Rule 23(a)
The proposed Class, based on the shortened Class Period, meets all four Rule 23(a) prerequisites. The first three prerequisites are easily met in this case and are undisputed by Defendants. For the sake of brevity, the Court will dispense with an in depth analysis and will find that the numerosity, commonality, and typicality prerequisites are satisfied.
The parties' dispute centers on the adequacy prerequisite. This prerequisite has two components: "1) the interests of the plaintiff and other members of the class must coincide; and 2) it must appear that plaintiff and his attorney will vigorously prosecute the action." In re Kirschner Med. Corp. Sec. Litig. ,
The Fourth Circuit has made clear that
[i]n a complex lawsuit, such as one in which the defendant's liability can be established only after a great deal of investigation and discovery by counsel against a background of legal knowledge, the representative need not have extensive knowledge of the facts of the case in order to be an adequate representative.
Gunnells ,
Notwithstanding the above, Defendants urge the Court to adopt a more searching inquiry into Flagstad's knowledge and control of the case, similar to that done by the District Court in Shiring v. Tier Technologies, Inc. ,
In Shiring , the court found that the plaintiff was an inadequate class representative because the record showed that he pursued litigation only after being prompted by counsel, took no significant steps to supervise the action, did not participate in drafting the complaint, and demonstrated a lack of knowledge regarding the allegations, including the positions held by the named defendants and why they were selected as defendants in the first place. Shiring ,
Although Shiring was decided after Gunnells and was a securities fraud case, decisions in this District have not required the heightened level of knowledge and control advocated for by Defendants. In Fangman v. Genuine Title, LLC , No. RDB-14-0081,
Examining the record here, it is clear that Flagstad does not have extensive knowledge of Emergent and its business beyond what is included in the Amended Complaint, the positions held by the individual Defendants, or the full procedural history of the case, and he has not demonstrated direct involvement in the drafting of the operative Amended Complaint or other filings. See ECF No. 78 at 18-22. He has, however, demonstrated that he has reviewed the Amended Complaint when it was filed and was familiar with its contents, has a general idea of the alleged misconduct and the legal basis for the lawsuit, and receives regular reports and communications from counsel regarding the progress of the case. Lead Pls.' Reply 3-10, ECF No. 87. He has also declared that he is committed to actively participating in and directing the litigation, including attending hearings, depositions, trial, and overseeing the preparation and filing of pleadings as well as to obtaining the largest recovery for the Class. Flagstad Decl., ECF No. 74; see Morris v. Wachovia Sec., Inc. ,
Flagstad, furthermore, need not be a lead plaintiff to qualify and be appointed as a class representative under Rule 23. Nothing in the PSLRA prohibits the appointment of a class representative who has not been previously appointed as a lead plaintiff. See 15 U.S.C. § 78u-4 (2012). Other jurisdictions have explicitly recognized that Rule 23 affirmatively permits the appointment of class representatives who were not named in the complaint. See, e.g. , In re Facebook, Inc., IPO Sec. & Derivative Litig. ,
Because Flagstad has demonstrated an understanding of his obligation to vigorously pursue litigation on behalf of the Class, is sufficiently informed about the facts of the case, receives regular reports and communications from counsel regarding the action, and shares the same interests as the other Class Members, the Court finds him to be an adequate class representative and thus the adequacy prerequisite of Rule 23(a) has been met, in addition to the other three prerequisites of the Rule.
C. The Proposed Class Satisfies Rule 23(b)(3)
Under Federal Rule of Civil Procedure 23(b)(3), class certification is proper only if (1) "the questions of law or fact common to class members predominate over any questions affecting only individual members," and (2) "that a class action is superior to other available methods for fairly and efficiently adjudicating the controversy." The "predominance" inquiry, the only element contested by Defendants in this case,3 "tests whether proposed classes are sufficiently cohesive to warrant adjudication by representation," and is "far more demanding" than the commonality prerequisite under Rule 23(a). Amchem Prods., Inc. v. Windsor ,
"Considering whether 'questions of law or fact common to class members predominate' begins, of course, with the elements of the underlying cause of action." Erica P. John Fund, Inc. v. Halliburton Co. (Halliburton I) ,
Here, Defendants argue that individual inquiry is required to prove the fourth and fifth elements-reliance and damages-of the proposed Class's claims. See ECF No. 69 at 18-26. Specifically, Defendants assert that individual issues will predominate because (1) the proposed Class is not entitled to the presumption of reliance under the fraud-on-the-market theory of liability to show classwide reliance, and (2) Lead Plaintiffs have not shown that damages can be calculated on a classwide basis. The Court disagrees with both contentions.
1. The Fraud-on-the-Market Presumption of Reliance Applies
Although proof of reliance is generally individualized, "[r]eliance can...be treated as a common issue if it is presumed under the theory that the defendants defrauded the market-not the individual plaintiffs-so long as the plaintiffs purchased their stock in an efficient market." Gariety v. Grant Thornton, LLP ,
The presumption of reliance can be rebutted at the class certification stage, however, if Defendants can show "that the asserted misrepresentation (or its correction) did not affect the market price of the defendant's stock." Halliburton II ,
Defendants contend that the proposed Class cannot avail itself of the fraud-on-the-market presumption of reliance in this case because Lead Plaintiffs have failed to show that the shares of Emergent Common Stock were traded in an efficient market, and, regardless, there was no price impact. ECF No. 78 at 30-34.
a. Lead Plaintiffs Sufficiently Show Market Efficiency
An efficient market includes "[l]arge numbers of rational and intelligent investors,' and '[i]mportant current information' that is 'almost freely available to all participants.' " Strougo v. Barclays PLC ,
To determine whether a security is traded in an efficient market, the Fourth Circuit has held that courts should consider "factors such as, among others, whether the security is actively traded, the volume of trades, and the extent to which it is followed by market professionals." Gariety ,
Relying on the opinions of their expert, Daniel S. Bettencourt ("Bettencourt"), Vice President of Crowninshield Financial Research, Inc., as set forth in his Report on Market Efficiency (ECF No. 70-1), Lead Plaintiffs assert that Emergent's Common Stock traded in an efficient market because all five Cammer factors are met as are the three factors articulated in the other widely-applied case of Krogman v. Sterritt ,
Defendants' only challenge Lead Plaintiffs' conclusion that the fifth, empirical Cammer factor cuts in favor of market efficiency in this case. ECF No. 78 at 32-33. Bettencourt performed two empirical tests from which he concluded that there was a cause and effect relationship between the announcement of the follow-on contract on June 22, 2016 and the subsequent fall in price of the Emergent Common Stock later that day. ECF No. 70-1 at 26-43. Defendants submit, relying on a report from their own expert, Rene Stulz, *688Professor at The Ohio State University, that the empirical tests Bettencourt performed were unreliable and accordingly inadmissible under Federal Rule of Evidence 702 and Daubert . ECF No. 78 at 32-33; see ECF No. 81. Thus, Defendants contend, market efficiency, cannot be established. ECF No. 78 at 32; Stulz Report 10, ECF No. 79-2. The Court disagrees.
Notwithstanding Defendants' contentions to the contrary, Lead Plaintiffs have sufficiently shown that Bettencourt's empirical tests are reliable, and are thus admissible. Bettencourt performed an event study on June 22, 2016 to test the impact of the corrective disclosure of the follow-on contract as well as two collective tests on the six earnings and guidance dates issued by Emergent to determine whether the dispersion of the residual price movements of Emergent's stock on those dates was significantly greater than the dispersion of residual price movements on all other dates during the purported Class Period. ECF No. 70-2 at 26, 35. An event study is the typical tool used by experts to directly show market efficiency. Strougo , 312 F.R.D. at 320-21 (citing Sanjai Bhagat & Roberta Romano, Event Studies and the Law: Part I: Technique and Corporate Litigation , 4 Am. L. & Econ. Rev. 141, 142 (2002) ). Additionally, experts routinely use, and courts accept, collective tests on the earnings and guidance dates like the one utilized by Bettencourt. See In re NII Holdings ,
Defendants do not take issue with Bettencourt's use of an event study to test for market efficiency; they only take issue with how Bettencourt performed the study, specifically accusing Bettencourt of selection bias in using June 22, 2016 as the date to study and for not performing additional analysis regarding the potential impact of other news and information disseminated during the purported Class Period. See ECF No. 79-2 at 32-35. Defendants do not, however, submit their own rebuttal event study, and so they neither provide a contrary conclusion on market efficiency nor an example of the "proper" methodology that should have been deployed in this case. Without more, Defendants' critiques go only to the credibility and weight of Bettencourt's opinions, not their admissibility. See PBM Prods., LLC v. Mead Johnson & Co. ,
Defendants further argue that Bettencourt failed to show that the collective tests are accepted in the field to demonstrate that a security traded in an efficient market.
*689At bottom, Bettencourt's empirical tests meet the reliability and relevancy standards under Daubert and Rule 702. Bettencourt comes forth with sufficient evidence to show that both the event study and collective tests performed are accepted methods to test market efficiency and were reliably applied to the facts and theories of this case. Any dispute as to the specific application of these tests in this case goes not to admissibility, but only to the expert's credibility and the weight to be given to his opinions.
The remainder of Defendants' argument against the admissibility of Bettencourt's opinions is that Bettencourt is unqualified to be an expert witness. Defs.' Mem. in Support of Mot. to Exclude Expert Op. 4-9, ECF No. 82. Defendants' attempt to discredit Bettencourt's testimony by attacking his experience, however, is unconvincing. Bettencourt's education and experience are sufficient to qualify him as an expert under Rule 702. See ECF 70-1 at 2-3 (listing Bettencourt's qualifications). Bettencourt has more than eight years of experience in applying economic, financial, and econometric analyses arising in securities and complex business litigation, and has worked on the expert opinions in a number of cases. ECF No. 70-1 at 2-3 (listing cases for which Bettencourt assisted in admitted expert testimony). The fact that his Report in this case is his first opinion as the lead expert is not fatal to the sufficiency of his credentials, nor does the fact that Defendants present a rebuttal expert who arguably has more impressive credentials. See Thomas J. Kline, Inc. v. Lorillard, Inc. ,
Even if the Court were to find Bettencourt's opinion regarding the fifth, empirical Cammer factor inadmissible, the Court would still find that Emergent's stock was traded in an efficient market. First, Emergent's stock traded on the NYSE, which creates a presumption of market efficiency. See, e.g. , In re DVI, Inc. Sec. Litig.,
Defendants fail to rebut this presumption, even if the Court disregards Bettencourt's empirical tests. As Bettencourt's Report shows, and which Defendants do not challenge, the other four Cammer factors are met, which is enough for the Court to conclude that the Emergent stock traded in an efficient market. See ECF No. 70-1 at 15-24; ECF No. 82 at 18-22. Courts have routinely found a market efficient based on a showing that the first four Cammer factors only are met. See, e.g. , Strougo , 312 F.R.D. at 321-22 (finding market efficiency based on the first four Cammer factors only because event studies test "for a degree that may not be required under Halliburton "); In re Comp. Sci. Corp. Sec. Litig. ,
*690Because the first four Cammer factors are met in this case, in addition to the Krogman factors, see ECF No. 70-1 at 15-21, which combined cover the three factors articulated in Gariety v. Grant Thornton, LLP , the Court concludes that Emergent's stock was traded in an efficient market.
b. Lead Plaintiffs Show Price Impact
Even if Emergent's stock traded in an efficient market, Defendants argue, Lead Plaintiffs nevertheless fail to show price impact, thereby rebutting the presumption of reliance, because they have not shown a significant impact on the stock price after any of the alleged misstatements. ECF No. 78 at 34. This argument, however, ignores the fact that Lead Plaintiffs' contention is premised on their allegation that because Defendants failed to disclose the truth about the follow-on contract during the proposed Class Period, Emergent's stock "traded at artificially inflated prices," and thus the decline of approximately $8 per share in Emergent's Common Stock price from June 21, 2016 to June 22, 2016 is an appropriate measure of price impact. See ECF No. 87 at 16.
The Supreme Court in Halliburton II made clear that a corrective disclosure is an appropriate landmark from which to determine price impact.
[T]he argument that there would be a positive impact on stock price from each of the allegedly false statements misstates [plaintiffs'] argument by suggesting that [the plaintiffs] [are] implying that the price of the stock rose as a result of the announcements, rather than simply remaining inflated because of these announcements. Additionally, this theory is not in keeping with the key principle underlying the efficient market theory, namely that in an efficient market material, unexpected information will be timely reflected in the stock price.
In re Comp. Sci. Corp. Sec. Litig. ,
Based on the foregoing, therefore, the Court concludes that Defendants have failed to rebut the presumption of reliance *691by showing that there was no price impact caused by the alleged misstatements. Ark. Teachers Ret. Sys. ,
2. Lead Plaintiffs Sufficiently Show that Damages Can Be Calculated on a Classwide Basis
Lead Plaintiffs assert, supported by Bettencourt's Report, that damages can be calculated on a classwide basis by using the standard measure of damages in Section 10(b) securities cases: the out-of-pocket per share or event study damages. ECF No. 70-1 at 44. Out-of-pocket damages "can be measured as the difference between the amount of stock price inflation at purchase and the amount of inflation in the stock price at sale taking into account formulaic prescriptions in relevant case law and statutes."
Defendants argue that Lead Plaintiffs fail to meet their burden based on Comcast Corp. v. Behrend ,
Defendants first argue that Lead Plaintiffs, similar to the plaintiffs in BP I , "provide no 'specifics of their proposed methodology,' as required by law," and on those grounds fail to meet Rule 23(b)(3). ECF No. 78 at 27 (quoting BP I ,
*692Defendants next argue that this case, "rather than being a typical stock-drop case (e.g., involving issues of accounting fraud), is akin to BP II ...." because Lead Plaintiffs are asserting liability based on materialization of an understated risk, similar to the plaintiffs in BP II . ECF No. 78 at 28 (citing BP II ,
Defendants' second argument also lacks merit. Defendants attempt to broaden Comcast beyond its plain meaning. Comcast was an antitrust case, and so it in no way announced a rule that plaintiffs in a securities fraud case must put forth any particular damages calculation methodology. Comcast , therefore is of no use in critiquing Lead Plaintiffs' proposal that classwide calculation of out-of-pocket damages is possible and appropriate in this specific case.
Defendants do not cite to a single Rule 10(b)-5 securities fraud case, and the Court could not find one, in which the court did not certify the proposed class based on the class's proposal of a sufficiently explained out-of-pocket damages model when the plaintiffs relied on a fraud-on-the-market theory of liability, which Lead Plaintiffs do here. See ECF No. 69 at 20-25; ECF No. 87 at 13-19. On the contrary, out-of-pocket damages calculations through an event study analysis as outlined in Bettencourt's Report have been recognized by courts as an accepted method for the evaluation of damages in securities fraud cases based on allegations similar to those made in this case. See, e.g. , Hatamian v. Advanced Micro Devices, Inc. , No. 14-cv-00226 YGR,
The Court agrees with Lead Plaintiffs that Defendants mischaracterize their theory of liability as "materialization of the risk." See ECF No. 87 at 17-18. Lead Plaintiffs make clear that they are alleging that because of Defendants' misrepresentations Emergent's stock was artificially inflated, and, as a result, investors suffered losses when the truth was revealed by the June 22, 2016 corrective disclosure. ECF No. 87 at 18. The amount of inflation resulting from the misrepresentations, therefore, would be same for each investor; regardless of their individual threshold for risk.
A number of courts have rejected similar attempts by defendants to reframe plaintiffs' theory of liability in order to prevent class certification in Rule 10(b)-5 securities fraud cases relying on the fraud-on-the-market theory of liability. See, e.g. , Baker v. SeaWorld Entm't, Inc. , No. 14cv2129-MMA (AGS),
For example, in Hatamian v. Advanced Micro Devices, Inc. , No. 14-cv-00226 YGR,
*693argument that the plaintiffs' proposed methodology of out-of-pocket damages calculation in their securities fraud case "is too crude to account for the complex theories of liability at issue." The defendants had argued that by merely evoking an event study methodology, plaintiffs failed to show that the methodology proposed could track the plaintiffs' theories of liability as required by Comcast . Hatamian ,
In Howard v. Liquidity Services ,
The Court similarly finds that Lead Plaintiffs' proposal of an event study to measure out-of-pocket per share damages meets their burden to show that damages can be calculated on a classwide basis. Because Lead Plaintiffs additionally have shown that the fraud-on-the-market presumption of reliance applies, the Court finds that the predominance prong of Rule 23(b)(3) is met. Accordingly, based on the foregoing, the Court finds that the proposed Class meets the predominance and superiority requirements under Rule 23(b)(3).
4. Class Counsel
The parties do not dispute that Robins Geller meets all of the requirements under Federal Rule of Civil Procedure 23(g)(1)(A) to serve as Class Counsel. Robbins Geller has been appointed class counsel in hundreds of securities class actions and has competently met its obligations under Rule 23 in those cases. The Court has no doubt that Robbins Geller will meet its obligation here to vigorously pursue this litigation. Accordingly, the Court will appoint Robbins Geller as Class Counsel.
5. Conclusion
Based on the foregoing, the Court will grant Lead Plaintiff's Amended Motion for *694Class Certification [ECF No. 68] and will certify the proposed Class based on the shortened Class Period, appoint Flagstad as Class Representative, and appoint Robbins Geller as Class Counsel. A separate order will follow.
322 F. Supp. 3d 676 (City of Cape Coral Mun. Firefighters' Ret. Plan v. Emergent Biosolutions, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.